"The dividend cutting of the PSEC11 Was it a mismanagement?"
Oh, no. The April 2026 numbers dismantle this reading. The fund generated R$ 0,69 per share of distributed result — 25% above the R$ 0,55 that you have actually paid. The difference R$ 0,14 did not evaporate: they rebuilt the reserve from almost zero to R$ 0,18/unit in a single month. The cut was not a symptom of weakness; it was the decision that released the fund to rotate the FII portfolio to CRI without distributing equity. The right question stopped being "why did they cut it?" and became "when did he get back up?".
When PSEC11 (ex-RVBI11) cut the dividend from R$ 0,65 to R$ 0,55 in April, the market treated as the third cut of a melting trajectory. It was the third reduction since R$ 0,75 — and serial cuts are usually red flags. But the April Management Report (ID 1200953, released in May) brought a data that was not in the price of the unit: the fund is generating more cash than it distributes. This reanalysis dissects where this box comes from, what accelerated rotation to CRI changes in the future load and why the grade has risen — even with caution.
What has changed in the analysis
The previous analysis treated the PSEC11 as a FoF (fund fund) in identity crisis: cutting divide every few months, with an indigestible merger (BPFF11 + HGFF11) and a vague promise to "turn credit." Skepticism was just — promise of transition is worth less than execution of transition.
The April Management Report changed the record because it stopped being a promise and became a number. Three new facts:
- The distributable result exceeded the DPS. R$ 0,69 generated against R$ 0,55 paid. For the first time in months, the fund distributes less than it produces — the opposite of who is "eating the estate" to support by dividing.
- The reserve has been rebuilt. It left R$ 0,00 (mar/26) for R$ 0,18/unit (apr/26) in 30 days. This is a mattress to soften weak months — just what was missing.
- The C.R.I. started to charge for real. Credit securities contributed with R$ 0,23/unit only in interest in the month. In February, the CRI was 14,6% of the PL; in April, 21,6%. Cargo machine's on.
The unit price (R$ 58,04 on 09/06) still emulates the pessimism of the "fund that cuts by dividing". The April Report suggests that this discount is looking at the rearview mirror.
The mathematics of R$ 0,69 versus R$ 0,55
Before the number, the concept — because the difference between "distributable result" and "distributed DPS" is the key to everything.
Distributable result is all the cash that the fund generated in the month: CRI interest, dividends of the FIIs it holds, income of the applied cash and realised earnings. Distributed DPS That's what he decided to pay the unitholder. The difference goes to the reserve — an accumulated mattress that can be used to support dividends in bad months. Distribute less what is generated is not avarice: it is to build safety margin.
Now the account, in absolute values. With 18,4 million units:
| Component | By unit | Total in the month |
|---|---|---|
| Distributable result generated | R$ 0,69 | R$ 12,7 Mi |
| — of which: CRI interest | R$ 0,23 | R$ 4,2 Mi |
| — remaining: FIIs + FoF + box | R$ 0,46 | R$ 8,5 Mi |
| DPS distributed to the unit | R$ 0,55 | R$ 10,1 Mi |
| Sobra → reserve | R$ 0,14 | R$ 2,6 Mi |
Look at the CRI line. R$ 0,23/interest unit in one month equals R$ 4,2 million — or about R$ 50 million per year at annualized rhythm (run-rate). And that with CRI occupying only 21,6% of the portfolio. It is this line that will define the future of the dividend, as we shall see.
The uncomfortable point that the skeptic would raise: "but R$ 0,46/unit still come from FIIs and box — and the fund is just selling the FIIs". That's right, and it's the transition knot. The FII recipe tends to fall as the wallet shrinks; the CRI recipe needs to grow fast enough to compensate and exceed. April showed that for now the sum is positive — and remaining.
The rotation FII → CRI in numbers
Why trade I.I.D. for I.R.? Because the CRI carries more. One CRI (Certificate of Real Estate Receipts) is a debt security backed on real estate receivables — the fund lends and receives contracted interest, usually IPCA+ or CDI+. In PSEC11, the average rate of CRIs linked to IPCA is IPCA+10,8% per year (marked the market, reaches IPCA+11,2%). Compare with the average dividend Yield of a brick/paper FoF in the 12% range — only the CRI delivers this spread by contract, with defined time and flow, while the FII DY oscillates with the market.
The speed of the exchange is what impresses:
| Marco | CRI (% PL) | Movement |
|---|---|---|
| Feb/2026 | 14,6% | baseline |
| Apr/2026 | 21,6% | +7 p.p. in 2 months · 38 operations · R$ 295 Mi |
| Target Dec/2026 | ~40% | FIIs fall from 79 to 40-50 assets |
In April, R$ 76 million allocated in 7 new CRIs, at average rates of IPCA+10,6% and CDI+5,0%. The CRI portfolio has become diversified (38 operations, IPCA 50% / CDI 42% / pre 8%), with quality names at the top: WTC (CDI+ZX3ZQX, 4,6% PL), Carrefour (pre 14%, 1,8%), Cabreuv (logistics, IPCA+ZX7ZQX) and Hive (residencial, IPCA+ZX8ZQX).
Now the projection that matters. Today the CRI to 21,6% of PL generates ~R$ 0,23/unit/month interest. If the allocation reaches the ~40% target of PL — practically doubling — the CRI load tends to approximate R$ 0,46/unit/month, adding about R$ 0,23/unit to the distributable result, everything more constant. This is the mathematical engine behind the guidance to raise the DPS in the second semester: it is not optimism, it is the contracted load of the titles that are entering.
The detail that the account hides: doubling the CRI requires selling ~30 to 40 FIIs in a discounted market. Each FII sold below cost performs damage and removes dividend. The CRI load needs to get in faster than the FII recipe comes out. In April the equation closed — but it is a race against the clock, not a guaranteed result.
When does the DPS go back up?
The management signaled maintaining R$ 0,55 until at least June, with "expectation of elevation in the 2nd semester". Translating the guide into verifiable premises, the DPS goes back up if:
- The CRI continues to advance towards 30-40% of the PL. Each percentage point of added CRI is new contracted cargo. Monitor the % of CRI in the next reports — it is KPI number one.
- The sale of the FIIs does not cause any material injury. If the fund is forced to liquidate assets far below the equity value, the carrying gain is partially eaten by loss of capital.
- The reserve remains above zero. R$ 0,18/unit is a thin mattress. If it grows month by month, the management gains comfort to raise the payment; if it zeros again, the increase delays.
- The cashier doesn't just stand there. The R$ 73 Mi (5,4%) box yields RF, not the CRI spread. The faster it is allocated, the sooner the result accelerates.
It's a guidance anchored in wallet mechanics, not cheerleading. But it depends on execution — and discounted market execution is precisely the risk.
The risks that remain
The turn of diagnosis does not erase the weaknesses. Four deserve weight:
- Injury to the sale of FIIs. Selling 30-40 funds in discounted market can crystallize losses. The CRI load pays off in the flow, but the asset value can bleed on the way.
- Performance rate in year of strong IFIX. Administration charges 0,925% a.a. on the market value (not over PL) plus 20% than exceeds IFIX. With IFIX +3,6% in the 1st quarter of 2026, hitting the index is difficult — and ironically, if the background performs well, the performance rate compresses the distributable result.
- 26,8% in FIIs Private Placement. It's funds. not listed in exchange (R$ 374 Mi) — purchased in private placement without daily market marking. In a liquidity stress, selling this piece is slow and can come out with disarray. It's the illiquid corner of the wallet.
- BPFF+HGFF merger units. About 25,000 shareholders inherited from the consolidation may not want a credit fund and pressure the sale of the unit — supporting the P/VP discount for longer.
There are also two CRIs in watchlist, but contained risk: Medabil (PL 0,2%) — a company in judicial recovery, but the CRI follows the default via insurance; and Cortel II (PL 0,3%) — restructured with deficiency up to Oct/27 and interest adjusted for IPCA+7,5%. Small exhibitions, monitored, no materiality for the result.
Q/VP 0,78: Does the discount make sense?
O P/VP (price over equity) from 0,78 means that the unit negotiates the R$ 58,04 while the equity by unit is R$ 74,12 — you buy R$ 1,00 of assets by paying R$ 0,78. On a stable background, discount 22% would be obvious opportunity. Here the discount has cause: the market prejudges (a) the uncertainty of the transition, (b) the risk of injury in the sale of the FIIs and (c) the illiquidity of the 26,8% in Private Placement. It's not a "free" discount — it's a work fund discount. The question is whether the work is advancing: April suggests yes.
Who should come in and who should wait
It might make sense to come in. for the investor who: accepts execution risk in exchange for increasing load; understands that he is buying a transition thesis (FoF → credit) with P/VP of 0,78 as margin; and has horizon to wait for the CRI to reach 30-40% of the PL over 2026. For this profile, the distributed R$ 0,69 and the rebuilt reserve are exactly the first validation signals he expected.
You must wait. Who: seeks predictable income month to month (PSD can still oscillate during rotation); does not tolerate carrying out loss in the portfolio; or either evidence of several months of result above the DPS before trusting the turn. For this investor, it is worth following one or two more management reports — the thesis goes nowhere, and confirmation costs little in lost return.
Verdict
Note: 5,5/10 — NEUTRO WITH CAUTELA / KEEP WITH CAUTELA. Revised Verdict positively in relation to the previous analysis. 23o of 30 in the Hybrid bucket, next to TRXY11 (5,5), ahead of RBRL11 (4,8) and TRXB11 (4,3).
The R$ 0,65 DPS cut to R$ 0,55 was not a sign of weakness — it was the lever that released the rotation. The April Report proved: R$ 0,69 distributable result against R$ 0,55 paid, rebuilt reserve from zero to R$ 0,18/unit and CRI jumping from 14,6% to 21,6% from PL in two months, loading R$ 4,2 Mi of interest in the month (~R$ 50 Mi/year in run-rate). If the allocation doubles to the goal of ~40%, the CRI load can add ~R$ 0,23/unit to the result — the concrete arithmetic base of the guide to elevate the DPS in the second semester.
Caution remains fair: selling 30-40 FIIs in discounted market can make damage, performance rate is a strong IFIX reducer in year and 26,8% in Private Placement are the illiquid corner of the portfolio. But the diagnosis changed from "deep melting" to "Deep in transition that began to deliver". . For those who accept risk of execution, the P/VP of 0,78 is margin; for those who want predictable income, it is worth waiting for confirmation of a few more months.
Sources: Management Report PSEC11 Apr/2026 (ID 1200953), 09/06/2026 quotation data. Informational and educational content — does not constitute a recommendation for purchase or sale. Investment decisions are the investor's responsibility.
